lm 10

Selective tryptophan 2, 3-dioxygenase (TDO) inhibitor (IC50 values are 0.62 and 2 μM for human and mouse TDO, respectively). Exhibits selectivity for TDO over IDO, MAO-A, MAO-B, and a panel of receptors and transporters. Reduces growth of TDO-expressing P

LM22B-10, an activator of the TrkB/TrkC neurotrophin receptor, can induce activation of TrkB, TrkC, ERK, and AKT both in vitro and in vivo.

PLM-101-C3-NHBoc is a ligand-linker conjugate targeting RET, which can be utilized in the synthesis of PROTACRETDegrader 2.

PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, contributing to its anti-leukemic effects. The compound's antitumor efficacy is demonstrated in both a mouse MV4-11 flank xenograft model (doses of 3 and 10 mg/kg; po) and an allogeneic xenograft mouse model (dose of 40 mg/kg; po) [1].

LM-108 is a monoclonal antibody that targets CCR8. It selectively eliminates tumor-infiltrating regulatory T cells (Treg) and is applicable to gastric cancer research.

AM679 is a potent and selective FLAP inhibitor with IC₅₀ values of 2.2 nM (FLAP binding), 0.6 nM (hLA), and 154 nM (hWB). AM679 displays improved CYP inhibition characteristics, no CYP3A4 time-dependent inhibition or induction, and strong in vivo leukotriene inhibition in rodent BAL models after oral administration.